This audio is auto-generated. Please let us know if you have feedback.
Dive Brief:
- Tandem Diabetes Care’s chief commercial officer Brian Hansen will resign from his role in December, according to a Friday securities filing.
- Hansen signed a separation agreement with the company that allows him to continue receiving his salary and bonuses until June 2024, effectively serving as a severance package.
- The departure is happening at the same time that Tandem is starting to roll out its new Mobi device, a miniaturized durable insulin pump.
Dive Insight:
Hansen has worked for Tandem since 2016, according to his LinkedIn account. Starting Dec. 29, he will no longer be chief commercial officer, but will continue to be a salaried employee on paid administrative leave through June, per the agreement.
Tandem hasn’t yet set out plans for hiring a new chief commercial officer. Its Mobi insulin pump received 510(k) clearance in June. The company plans to start an early access program for the device in the fourth quarter, and move forward with a commercial launch in early 2024, CEO John Sheridan said in an early August earnings call.
